Evidence map›Paper›PMID 35199280›Full record

ReviewReviews in endocrine & metabolic disorders2022

Novel treatments for congenital adrenal hyperplasia.

Mariska A M Schröder, Hedi L Claahsen-van der Grinten

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07099456 (Channelling Fertility And Sexual Function In Congenital Adrenal Hyperplasia. CALLIOPE), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07099456 recruitingnot on this mapstarted 2024, after this paper: background citation

Channelling Fertility And Sexual Function In Congenital Adrenal Hyperplasia. CALLIOPE: An Observational, Longitudinal Pilot Study

TypeobservationalSponsorUniversity of Roma La SapienzaRan2024 to 2030Enrolled50ConditionsCongenital Adrenal Hyperplasia (CAH)
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Approach to the Child and Adolescent With Adrenal Insufficiency.The Journal of clinical endocrinology and metabolism · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. A Humanized and Viable Animal Model for Congenital Adrenal Hyperplasia-International journal of molecular sciences · 2024
    Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mariska A M SchröderDepartment of Pediatrics, Amalia Childrens Hospital, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-2139-9076
Hedi L Claahsen-van der GrintenDepartment of Pediatrics, Amalia Childrens Hospital, Radboud University Medical Center, Nijmegen, The Netherlands. Hedi.Claahsen@radboudumc.nl.ORCID http://orcid.org/0000-0003-0181-0403
Radboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) need life-long medical treatment to replace the lacking glucocorticoids and potentially lacking mineralocorticoids and to lower elevated adrenal androgens. Long-term complications are common, including gonadal dysfunction, infertility, and cardiovascular and metabolic co-morbidity with reduced quality of life. These complications can be attributed to the exposure of supraphysiological dosages of glucocorticoids and the longstanding exposure to elevated adrenal androgens. Development of novel therapies is necessary to address the chronic glucocorticoid overexposure, lack of circadian rhythm in glucocorticoid replacement, and inefficient glucocorticoid delivery with concomitant periods of hyperandrogenism. In this review we aim to give an overview about the current treatment regimens and its limitations and describe novel therapies especially evaluated for 21OHD patients.

Indexed as

Adrenal Hyperplasia, CongenitalAndrogensGlucocorticoidsHormone Replacement TherapyHumansQuality of LifeAndrogensGlucocorticoids21-hydroxylase deficiencyAdrenocorticotropic hormone antagonistCongenital Adrenal HyperplasiaCorticotropin-releasing hormone receptor antagonistGlucocorticoid replacement therapyModified-releaseSteroid production inhibitors

Identifiers

PMID35199280
PMCPMC9156475
OpenAlexW4212786096

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.